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Tamoxifen resistance is a major cause of death in patients
with recurrent breast cancer. Current clinical factors can
correctly predict therapy response in only half of the
treated patients. Identification of proteins that are asso-
ciated with tamoxifen resistance is a first step toward
better response prediction and tailored treatment of pa-
tients. In the present study we intended to identify puta-
tive protein biomarkers indicative of tamoxifen therapy
resistance in breast cancer using nano-LC coupled with
FTICR MS. Comparative proteome analysis was per-
formed on 5,500 pooled tumor cells (corresponding to
550 ng of protein lysate/analysis) obtained through laser
capture microdissection (LCM) from two independently
processed data sets (n  24 and n  27) containing both
tamoxifen therapy-sensitive and therapy-resistant tu-
mors. Peptides and proteins were identified by matching
mass and elution time of newly acquired LC-MS features
to information in previously generated accurate mass and
time tag reference databases. A total of 17,263 unique
peptides were identified that corresponded to 2,556 non-
redundant proteins identified with >2 peptides. 1,713
overlapping proteins between the two data sets were
used for further analysis. Comparative proteome analysis
revealed 100 putatively differentially abundant proteins
between tamoxifen-sensitive and tamoxifen-resistant tu-
mors. The presence and relative abundance for 47 differ-
entially abundant proteins were verified by targeted
nano-LC-MS/MS in a selection of unpooled, non-micro-
dissected discovery set tumor tissue extracts. ENPP1,
EIF3E, and GNB4 were significantly associated with pro-
gression-free survival upon tamoxifen treatment for
recurrent disease. Differential abundance of our top dis-
criminating protein, extracellular matrix metalloproteinase
inducer, was validated by tissue microarray in an independ-
ent patient cohort (n  156). Extracellular matrix metallo-
proteinase inducer levels were higher in therapy-resistant
tumors and significantly associated with an earlier tumor
progression following first line tamoxifen treatment (hazard
ratio, 1.87; 95% confidence interval, 1.25–2.80; p 0.002). In
summary, comparative proteomics performed on laser
capture microdissection-derived breast tumor cells us-
ing nano-LC-FTICR MS technology revealed a set of
putative biomarkers associated with tamoxifen therapy
resistance in recurrent breast cancer. Molecular &
Cellular Proteomics 8:1278–1294, 2009.
Tamoxifen is an antiestrogenic agent that has been widely
and successfully used in the treatment of breast cancer over
the past decades (1). Tamoxifen targets and inhibits the es-
trogen receptor-, which is expressed in 70% of all primary
breast tumors and is known to be important in the develop-
ment and course of the disease. When diagnosed at an early
stage, adjuvant systemic tamoxifen therapy can cure 10%
of the patients (1). In recurrent disease, 50% of patients
have no benefit from tamoxifen (intrinsic resistance). From the
other half of patients who initially respond to therapy with an
objective response (OR)1 or no change (NC), a majority even-
tually develop progressive disease (PD) due to acquired ta-
moxifen resistance (2, 3). With the markers available to date
we can insufficiently predict therapy response. Therefore,
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identification of new biomarkers that can more effectively
predict response to treatment and that can potentially func-
tion as drug targets is a major focus of research.
The search for new biomarkers has been enhanced by the
introduction of microarray technology. Gene expression stud-
ies have resulted in a whole spectrum of profiles for e.g.
molecular subtypes, prognosis, and therapy prediction in
breast cancer (4–10). Corresponding studies at the protein
level are lagging behind because of immature technology.
However, protein-level information is crucial for the functional
understanding and the ultimate translation of molecular
knowledge into clinical practice, and proteomics technologies
continue to progress at a rapid pace.
Proteomics studies reported so far have mainly been per-
formed with breast cancer cell lines using either two-dimen-
sional gel electrophoresis (11–14) or LC-MS for protein sep-
aration (15–17). However, it is known that the proteomic
makeup of a cultured cell is rather different from that of a
tumor cell surrounded by its native microenvironment (18).
Furthermore cell lines lack the required follow-up information
for answering important clinical questions. In addition, tumor
tissues in general and breast cancer tissues in particular are
very heterogeneous in the sense that they harbor many dif-
ferent cell types, such as stroma, normal epithelium, and
tumor cells. LCM technology has emerged as an ideal tool for
selectively extracting cells of interest from their natural envi-
ronment (19) and has therefore been an important step for-
ward in the context of genomics and proteomics cancer bi-
omarker discovery research. LCM-derived breast cancer
tumor cells have been used for comparative proteomics anal-
yses in the past using both two-dimensional gel electrophore-
sis (20, 21) and LC-MS (22). This has resulted in the identifi-
cation of proteins involved in breast cancer prognosis (21) and
metastasis (20, 22). Although these studies demonstrated that
proteomics technology has advanced to the level where it can
contribute to biomarker discovery, major drawbacks, such as
large sample requirements (42–700 g) and low proteome
coverage (50–76 proteins), for small amounts of starting ma-
terial (1 g) persist. Because clinical samples are often
available in limited quantities, in-depth analysis of minute
amounts of material (1 g) necessitates advanced technol-
ogies with sufficient sensitivity and depth of coverage.
Recently we demonstrated the applicability of nano-LC-
FTICR MS in combination with the accurate mass and time
(AMT) tag approach for proteomics characterization of
3,000 LCM-derived breast cancer cells (23). This study
showed that proteome coverage was improved compared
with conventional techniques. The AMT tag approach initially
utilizes conventional LC-MS/MS measurements to establish a
reference database of AMT tags specific for a particular pro-
teome sample (e.g. breast cancer tissue). Each tag consists of
a theoretical mass calculated from the peptide sequence, an
LC normalized elution time (NET) value, and an indicator of
quality. The AMT tag database serves as a “lookup table” for
identifying peptides in subsequent quantitative LC-MS anal-
yses. Substituting routine LC-MS/MS analyses (shotgun ap-
proach) with LC-FTICR MS analyses (AMT tag approach)
significantly increases overall throughput and sensitivity while
reducing sample requirements. Additionally quantitative in-
tensity information related to the abundance of the protein
can be discerned from these MS analyses (24). In the present
study, we used the same strategy to analyze eight pools of
tumor cells in duplicate or triplicate (resulting in 19 samples)
derived from 51 fresh frozen primary invasive breast carcino-
mas that appeared to be either sensitive or resistant to ta-
moxifen treatment after recurrence. This work resulted in the
identification of a putative protein profile associated with ta-
moxifen therapy resistance. In addition, the top discriminating
protein of the putative profile, extracellular matrix metallopro-
teinase inducer (EMMPRIN), was validated in an independent
patient cohort and was significantly associated with resist-
ance to tamoxifen therapy and shorter time to progression
upon tamoxifen treatment in recurrent breast cancer.
EXPERIMENTAL PROCEDURES
Patients and Tumor Tissues—For the discovery phase of the study,
51 different fresh frozen primary breast cancer tissues from our liquid
N2 tissue bank were used. Primary tumors were selected from pa-
tients that did not receive any systemic adjuvant hormonal therapy
and were treated with the antiestrogen tamoxifen as first line therapy
upon detection of recurrent breast cancer. Furthermore tumors were
selected on the basis of positive estrogen receptor- expression as
assessed by ligand binding assay or enzyme-linked immunosorbent
assay (10 fmol/mg of cytosolic protein). Tumor tissues were divided
into two classes based on the type of response to tamoxifen therapy.
24 tumors were sensitive to tamoxifen therapy, showing either com-
plete remission (CR) or partial remission (PR), and were assigned as
OR. 27 tumors were resistant to therapy, showing an increase in
tumor size, and were designated as PD. Clinical response was de-
fined by standards of the International Union against Cancer criteria of
tumor response (25). 20 of the above mentioned tumor tissues were
selected for the verification study. Tissues were included based on
their high tumor cell content of70%. Tumor cell content was judged
after hematoxylin/eosin stain of a separately cut 4-m tissue section.
For immunohistochemical validation, a primary breast tissue mi-
croarray (TMA) containing 0.6-m cores of formalin-fixed paraffin-
embedded tumors was used. Within the TMA, there were 156 tumor
tissues from patients that received tamoxifen as first line treatment
upon recurrence. Median follow-up of patients alive after primary
surgery was 103 months (range, 16–222 months) and 51 months after
the onset of tamoxifen treatment (range, 9–136 months). Included
patients showed CR, PR, PD, and NC of 6 and 6 months. Further
patient and tumor characteristics are summarized in Table IV.
This study was approved by the Medical Ethics Committee of the
Erasmus Medical Center Rotterdam, The Netherlands (MEC 02.953)
and was performed in accordance to the Code of Conduct of the
Federation of Medical Scientific Societies in The Netherlands, and
wherever possible we adhered to the Reporting Recommendations
for Tumor Marker Prognostic Studies (REMARK) (26).
Laser Capture Microdissection—LCM was performed on 8-m
tissue cryosections that were fixed in ice-cold 70% ethanol and
stained with hematoxylin as described previously (27). Briefly slides
were washed in Milli-Q water, stained for 30 s in hematoxylin, washed
again in Milli-Q water, subsequently dehydrated twice in 50, 70, 95,
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and 100% ethanol for 30 s each, and air-dried. Laser microdissection
and pressure catapulting was performed directly after staining. Tumor
epithelial cells were collected, using a P.A.L.M. LCM device, type
P-MB (P.A.L.M. Microlaser Technologies AG, Bernried, Germany).
From each cryosection an area of 500,000 m2 that corresponds to
4,000 cells (area  slide thickness/1,000-m3 cell volume) was
collected in P.A.L.M. tube caps containing 10 l of 0.1% RapiGest
(Waters Corp., Milford, MA) and then spun down into 0.5-ml Eppen-
dorf Protein LoBind tubes (Eppendorf, Hamburg, Germany). Collected
cells were stored at 80 °C until further processing. Because we
used small numbers of microdissected cells in this study, the protein
concentration was typically below the detection limit of any protein
assay. Hence the protein concentration for samples undergoing
LC-MS analysis was estimated based on microdissected tissue area
and extrapolations from protein assays performed on whole tissue
lysates (i.e. 4,000 cells corresponds to 400 ng of total protein).
Sample Preparation—Microdissected cell batches were pooled
into OR and PD tumor groups (corresponding to 25,000 cells/pool)
prior to sample preparation. Briefly cells were lysed by sonication
directly in RapiGest solution using an Ultrasonic Disruptor Sonifier II
(Model W-250/W-450, Branson Ultrasonics, Danbury, CT) for 1 min at
60% amplitude. Proteins were subsequently equilibrated for 2 min at
37 °C, denatured at 99 °C for 5 min, and processed for overnight
trypsin digestion according to the instructions of the manufacturer
using MS-grade porcine modified trypsin gold (Promega, Madison,
WI) at a 1:20 (w/v) ratio as described previously (23). Digestion was
stopped by incubation with 0.5% TFA at 37 °C for 30 min. Remaining
cellular debris were spun down for 20 min at 10,600  g, and
supernatant was transferred to a new Eppendorf LoBind cup. Pep-
tides were lyophilized and stored at80 °C until further analysis. Prior
to FTICR MS analysis, samples were reconstituted in 18 l of
NH4HCO3, vortexed briefly, and spun down again for 10 min at
10,600  g to pellet any contaminating particulate material.
For the verification study, whole tissue lysates were prepared from
20 tumor tissues from which 6  4-m cryosections per sample were
cut. Tissue cryosections were placed in a Teflon container, frozen in
liquid N2, and then pulverized in a frozen state in a microdismembra-
tor (Braun Biotech International). The resulting powder was resus-
pended in 100 l of 0.1% RapiGest. Cell lysis and trypsin digestion
were performed as described above. Prior to trypsin digestion, a BCA
protein assay (Pierce) was performed to determine protein concen-
tration. From each total tissue sample, 50 g of protein lysate was
used for trypsin digestion at a trypsin:protein ratio of 1:50 (w/w) and
further handled as described above.
Nano-LC-FTICR MS—Nano-LC-FTICR MS was performed using a
slightly modified procedure as described previously (23, 28). Each
pooled sample was analyzed in triplicate by injecting 4 l (equivalent
to 5,500 cells or 550 ng) directly via a 3-l sample loop onto a
custom-built reversed-phase (RP) 80-cm  50-m-inner diameter
fused silica capillary column (Polymicro Technologies, Phoenix, AZ)
packed in house with 3-m C18 particles (300-Å pore size; Jupiter,
Phenomenex, Torrence, CA) and subjected to an applied pressure of
10,000 p.s.i. through a high pressure syringe pump (ISCO, Lincoln,
NE). Flow rate over the column was  250 nl/min. After an injection
period of 45 min, peptides were eluted from the column using a
gradient from 100% mobile phase A (99.75% H2O, 0.2% acetic acid,
0.05% TFA) to 70% mobile phase B (90% acetonitrile, 9.9% H2O,
0.1% TFA) over a 200-min period. The nano-LC column outlet was
coupled on line to a 7-tesla FTICR mass spectrometer through a
nano-ESI emitter; 4,000 mass spectra were acquired in each LC-MS
analysis using 0.3-s ion accumulation time and 50-s gas pulse (29).
LC-MS/MS—In the verification study, tryptic digests of 20 different
whole tissue lysates (8 OR and 12 PD) were analyzed on a custom-
built RPLC system via ESI utilizing an ion funnel (30) coupled to a
ThermoFisher Scientific LTQ-Orbitrap mass spectrometer (Thermo-
Fisher Scientific, San Jose, CA). Separation was performed using a
custom-made column (60 cm  75-m inner diameter) packed in
house with Jupiter particles (C18 stationary phase, 5-m particles,
300-Å pore size). The capillary RPLC system used for peptide sepa-
rations has been described previously (23, 28). Mobile phase A con-
sisted of 0.1% formic acid in water, and mobile phase B consisted of
100% acetonitrile. The column was equilibrated at 10,000 p.s.i. with
100% mobile phase A. A mobile phase selection valve was switched
50 min after injection to create a near exponential gradient as mobile
phase B displaced mobile phase A in a 2.5-ml mixer. A split was used
to provide an initial flow rate through the column of 400 nl/min. The
column was coupled to the mass spectrometer using an in-house
manufactured ESI interface with homemade 20-m-inner diameter
chemically etched emitters (31). The heated capillary temperature and
spray voltage were 200 °C and 2.2 kV, respectively. Mass spectra
were acquired for 80 min over them/z range 400–2,000 at a resolving
power of 100,000. An inclusion list with m/z values corresponding to
peptide masses of 100 target proteins was used to select precursor
ions. In cases when no targeted precursor ion was present, a maxi-
mum of six data-dependant LTQ tandem mass spectra were re-
corded for the most intense peaks in each survey mass spectrum.
Protein Identification and Quantitation—FT mass spectra, acquired
with the 7-tesla FTICR or LTQ-Orbitrap, were processed using ICR-
2LS, Decon2LS (32), and VIPER v3.39 software developed in house
(33). The output data files were visualized as two-dimensional dis-
plays of peptide monoisotopic mass versus LC elution time (i.e.
spectrum number). Next MS peaks with similar measured neutral
masses and LC elution times were clustered to form LC-MS features
(or unique mass classes). LC elution times were converted into NET to
make multiple LC-MS runs comparable (34). The assembled set of
LC-MS features was then searched against the human mammary
epithelial cell line AMT tag database (35), MCF-7 epithelial breast
carcinoma cell line AMT tag database (36), and a composite database
for a mixture of human mammary epithelial cells and MCF-7-c18,
BT-474, MDA-231, and SKBR-3 breast cancer cell lines (37) using
stringent filtering criteria: Xcorr 1.5, 2.7, and 3.3 for 1, 2, and 3
fully tryptic peptides, respectively, and Xcorr 3.0, 3.7, and 4.5 for
1, 2, and 3 partially tryptic peptides (with a minimum length of 6
amino acids), respectively, as reported previously (23). The LCM-
SWARP (liquid chromatography-based mass spectrometric warping
and alignment of retention times of peptides) algorithm (38) was used
to match LC-MS features to AMT tags. A tolerance window of mass
measurement accuracy 6 ppm and NET error 0.025 was applied
to ensure reliable peptide identification with false discovery rate of
10%. Identified peptides were coupled to their corresponding pro-
teins using the human International Protein Index (IPI) databases,
2006 version 3.20 including 61,255 protein entries (discovery phase)
and 2008 version 3.39 including 69,731 protein entries (verification
phase), and in-house built Qrollup v2.2 software. Two or more con-
stituent peptides were required to confidently identify a protein. In the
case of proteins with multiple splice isoforms, these isoforms
were only specifically listed if they were identified by at least one
unique peptide (in addition to overlapping peptide sequences). For
average abundance calculation, only highly abundant and, where
possible, unique peptides were used. Protein names and descriptions
were then converted to TrEMBL, NCBI (National Center for Biotech-
nology Information), and Swiss-Prot database formats. Protein infor-
mation was retrieved from European Molecular Biology Laboratory-
European Bioinformatics Institute databases. Proteins identified from
all available AMT tag databases were assembled into a single list,
giving rise to some redundancy. A final non-redundant protein list was
generated using ProteinProphet software (SourceForge, Inc.). MS
peak intensities were used as a measure of the relative peptide
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abundances. The mean abundance of the LC-MS features was used,
and the relative abundances of constituent peptides were averaged to
derive the relative abundance of the parent protein.
Tandem mass spectra acquired with the LTQ-Orbitrap were
searched against the human IPI 2008 database using TurboSEQUEST
v27. We used in-house developed DeconMSn software to correct the
monoisotopic masses prior to generation of the dta files used for
subsequent database search. Peptide sequences were considered
confident with the following filtering criteria: Xcorr of 1.9, 2.2, and 3.75
for 1, 2, and 3 peptides and Cn  0.1. We also applied the
AMT tag strategy to identify peptides in survey mass spectra acquired
with the LTQ-Orbitrap by matching the accurate masses and elution
times against the composite breast cancer cell line AMT database.
Peak intensities measured in high resolution survey spectra were
used to retrieve relative abundance information as described above.
Immunohistochemistry—Immunohistochemical validation was per-
formed with an in-house prepared TMA. The TMA was established in
close collaboration with a dedicated pathologist (M. A. d. B.) who
evaluated all tissues for histology, grade, and Bloom and Richardson
scoring (39). Tissue sections of 4 m were stained overnight at 4 °C
for EMMPRIN using a 1:100 diluted antibody directed against the C
terminus of the protein (8D6, sc-21746, Santa Cruz Biotechnology,
Inc., Santa Cruz, CA). Antigen retrieval was performed prior to anti-
body incubation for 40 min at 95 °C using DAKO retrieval solution, pH
6 (DakoCytomation, Carpinteria, CA) after which the slides were
cooled down to room temperature. Staining was visualized using the
anti-mouse EnVision System-HRP (DAB) (DakoCytomation) ac-
cording to the instructions provided by the manufacturer. Scoring
of immunostaining was performed by two independent observers
who recorded both percentage of positive tumor cells and staining
intensity.
Data Analysis and Statistics—Relative abundance levels of all iden-
tified proteins in one sample were intra- and intersample normalized
by log2 transformation using in-house developed MultiAlign software
v1.1. Subsequently Z-score normalization was applied to each pro-
tein across the samples using the formula (value  mean)/standard
deviation. Sample sets 1 and 2 were separately Z-score-normalized
to correct for time and experimental variation. Normalized values
were subjected to class comparison and prediction analysis using
BRB-ArrayTools version 3.5.0 beta1 developed by Dr. Richard Simon
and Amy Peng Lam. Class comparison involved finding differentially
abundant proteins between therapy-sensitive (OR) and therapy-resis-
tant (PD) tumors using a univariate two-sample t test with a signifi-
cance threshold of 0.05. All data from sample sets 1 and 2 were
combined to create a general list of differentially abundant proteins
between OR and PD tumors and subjected to a Mann-Whitney Wil-
coxon rank sum test performed with the STATA statistical package,
release 10.0 (STATA, College Station, TX).
Hierarchical clustering of the data was performed using the OmniViz
Desktop 3.8.0 package. For clustering, average linkage and the Euclid-
ian similarity metric were used. Principal component analysis (PCA) was
performed using Spotfire DecisionSite 8.1, version 14.3.
Kaplan-Meier survival analysis as a function of time to progression
after the onset of first line tamoxifen treatment as well as correlation
with response and other clinical parameters was performed using
STATA. The primary end point for the Cox proportional hazard model
was disease progression after the onset of tamoxifen treatment.
RESULTS
Protein Identification by Nano-LC-FTICR MS—Large scale
protein identification is a pivotal step in the discovery of a
predictive protein profile. We have previously shown that
nano-LC-FTICR MS coupled to AMT tag-based protein iden-
tification provides the sensitivity and proteome coverage re-
quired to achieve this goal (23). In the present study, we
describe the clinical applicability of this approach by analyz-
ing the proteome of eight pools of tumor cells procured by
LCM from breast cancer tissues derived from 24 tamoxifen
therapy-sensitive and 27 therapy-resistant patients. Fig. 1
summarizes our study design.
Tryptic peptides corresponding to550 ng of protein lysate
were analyzed using nano-LC-FTICR MS. Resulting data sets
were visualized in a form of a two-dimensional plot, displaying
monoisotopic mass versus spectrum number (NET) as shown
in supplemental Fig. 1. On average 40,000 LC-MS features
were detected in each analysis. These features were matched
against previously established breast (cancer) cell line AMT
tag databases. On average, 20% of LC-MS features
matched with peptides in the database and were thus iden-
tified as illustrated in supplemental Fig. 1B.
For this study, two sample sets were independently pre-
pared and analyzed, using a different set of tumors, as shown
in Fig. 2. Sample set 1 consisted of 24 tumors of which 11
were sensitive (OR) and 13 were resistant (PD) to tamoxifen
treatment. Sample set 2 contained 27 tumors, 13 OR and 14
PD tissues. Microdissected cells were pooled to average
sample heterogeneity and to enable triplicate analysis and
were analyzed by nano-LC-FTICR MS. Replicate MS analy-
ses, for which technical problems such as clogged tips were
observed, were excluded from further data analysis, leaving
19 LC-MS data sets for further analysis (Table I). In total,
17,263 peptides corresponding to 2,556 proteins were iden-
tified through AMT tag database matching. Between the two
sample sets 1,713 proteins, identified by 13,729 peptides,
were identical, corresponding to an overlap of 67% (Table I).
Protein abundance was computed by averaging intensities of
the highly abundant peptides identified for the given protein
and, where possible, using unique peptide sequences to ac-
count for multiple splice isoforms. It needs to be mentioned
that it is difficult to correctly assess average protein abun-
dance of highly homologous proteins that may have different
abundance levels if these proteins are identified through iden-
Laser capture microdissection
On-line ESI coupling
Cell lysis and trypsin digestion
Automated data processing
Primary tumor tissue
Enriched tumor cells
nLC peptide separation
FTICR MS
AMT tag DB search
Filtering
Protein identification
FIG. 1. Experimental flow chart. All steps from sample prepara-
tion, MS analysis, and protein identification are described in the text.
nLC, nano-LC; DB, database.
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tical peptides. In those cases, the additional use of unique
peptide sequences may partly overcome this problem. Infor-
mation on protein identification, such as filtering scores, as-
signed peptides and number of peptides used for abundance,
mass and NET errors, and additional information is reported in
supplemental Table S1. Normalized protein abundances for
1,713 proteins are displayed in supplemental Table S2.
Discovery of Tamoxifen Therapy Response-associated Pro-
teins—For the discovery of proteins that were associated with
tamoxifen resistance, the 1,713 overlapping proteins were
subjected to statistical analysis. The univariate two-sample t
test from BRB-ArrayTools was used to search for differentially
abundant proteins between OR and PD samples (Fig. 2).
Protein abundances from all OR and PD samples from the two
sample sets were analyzed together and compared with each
other. The BRB analysis resulted in a list of 153 discriminating
proteins using a significance threshold of p  0.05 (the com-
plete BRB analysis list is provided in supplemental Table S3).
These 153 proteins were subsequently subjected to a Wilc-
oxon rank sum test, which narrowed the list down to 100
proteins with a p value 0.05. These 100 differentially abun-
dant proteins were designated as a putative protein profile
associated with the type of response to tamoxifen therapy. In
this putative protein profile, 46 proteins had higher relative
abundance in PD, and 54 had higher abundance in OR tis-
sues. Protein information as well as OR:PD ratios and p values
are listed in Table II in which the order and numbering of
proteins corresponds to the order in Fig. 4. Our top discrim-
1. Methodology
Triplicate FTICR MS analysis, 500 ng tryptic digest on 50 µm x 80 cm C18-column
Sample set 1, n=24 Sample set 2, n=27
11 OR            13 PD 13 OR            14 PD
6 76 5 6 7
Pool 1
7 7
Pool 3Pool 1 Pool 3 Pool 4Pool 4Pool 2Pool 2
Hierarchical clustering + prediction
2. Discovery
t-test and  Wilcoxon ranking 
100 discriminatory proteins
BRB univariate t-test on 1713 
overlapping proteins (P< 0.05) 
4. Validation
OR set 1+ 2 PD set 1+ 2
3. Verification
8 OR,  12 PD
Total tissue protein lysates
nLC-MS/MS using inclusion list of 
peptide masses from 100 proteins
Verification of 50 proteins (MS/MS)    
quantification of 47 proteins (MS)
IHC validation of top discriminating protein, EMMPRIN, on TMA: 156 tam advanced tissues
Survival analysis
FIG. 2. Data analysis flow chart.
Tryptic digests from two independently
processed sample sets were analyzed in
triplicate by nano-LC-FTICR. MS peak
intensity-derived peptide/protein abun-
dances were subjected to statistical
analysis to determine differentially abun-
dant proteins between OR and PD sam-
ples in both sample sets combined as
well as in the two samples sets sepa-
rately. Subsequently hierarchical clus-
tering and class prediction was per-
formed. nLC, nano-LC.
TABLE I
FTICR MS summary
Peptide and protein information for LC-MS analyses that were used for further statistical analysis are summarized for sample set 1, set 2,
the combined set, and the overlap.
Data set Tumor set 1 Tumor set 2 Total Overlap sets 1  2
Number of analyzed samples 5 OR; 4 PD 5 OR; 5 PD 10 OR; 9 PD
Total unique peptides 14,933 16,059 17,263 13,729
Total unique proteins 1,998 2,271 2,556 1,713 (67%)
Tamoxifen Resistance Protein Profile in Breast Cancer
1282 Molecular & Cellular Proteomics 8.6
 at M
edical Library Erasm
us M
C on June 8, 2009 
w
w
w
.m
cponline.org
D
ow
nloaded from
 
TABLE II
Tamoxifen-response protein profile
Name, ratio, p value, IPI number, molecular mass, localization are given on the putative 100-protein profile. The order and numbering are
identical to Fig. 4. EPH, ephrin; snRNA, small nucleolar RNA; GDNF, glial cell-derived neurotrophic factor.
No.a Protein description
Ratio of
geometric
means,
OR:PD
Wilcoxon
rank sum IPI Gene symbol
Molecular
mass Localization
b
kDa
1 EPH receptor B2 0.458 0.0057 IPI00252979.7 EPHB2 (ERK, EPTH3) 110 Membrane
2 Splice isoform 1 of protein kinase
C and casein kinase substrate in
neurons protein 2
0.538 0.0366 IPI00027009.2 PACSIN2 56 Cytoplasm
3 40 S ribosomal protein S4, X
isoformc,d
0.478 0.0412 IPI00217030.5 RPS4X (SCAR) 29 Ribosome
4 Calponin-2c 0.478 0.0134 IPI00015262.9 CNN2 33.5 Cytoskeleton
5 Calgranulin Bc,d 0.483 0.0127 IPI00027462.1 S100A9 (CAGB, MRP14) 13 Cytoplasm
6 Anchor attachment protein 1 0.513 0.047 IPI00021594.2 GPAA1 68 ER
7 Epididymal secretory protein E1
precursor
0.54 0.0085 IPI00301579.3 NCP2 16.5 Secreted protein
8 Pyrroline-5-carboxylate
reductase 1c,d
0.49 0.0274 IPI00550882.2 PYCR1 (P5CR1) 33 u
9 Nucleolar protein NOP5c 0.453 0.0202 IPI00006379.1 NOP5 (HSPC120) 60 Nucleus
10 Annexin A8 0.394 0.0127 IPI00218835.4 ANXA8 (ANX8) 37 u
11 Lysyl-tRNA synthetasec,d 0.539 0.0127 IPI00014238.2 KARS (KIAA0070) 68 Cytoplasm
12 Syntaxin 7 0.484 0.0338 IPI00289876.2 STX7 30 Endosome
13 Splice isoform 2 of basigin
precursore
0.342 0.0004 IPI00019906.1 BSG (EMMPRIN, CD147) 42 Cell membrane
14 FLJ20625 protein 0.457 0.0411 IPI00016670.2 FLJ20625 18 u
15 Eukaryotic translation initiation
factor 5
0.491 0.003 IPI00022648.2 EIF5 49 Cytosol
16 Splice isoform 1 of Surfeit locus
protein 4c,d
0.449 0.0097 IPI00005737.1 SURF4 30 ER
17 Splice isoform 1 of calumenin
precursorc,d
0.514 0.0222 IPI00014537.1 CALU 38 ER/Golgi
18 Coronin-1Ac,d 0.507 0.0179 IPI00010133.1 CORO1A (CLIPINA) 51 Actin cytoskeleton
19 RAS-related protein RAB-10c 0.516 0.0412 IPI00016513.3 RAB10 22.5 Cell membrane
20 Splice isoform long of potential
phospholipid-transporting
ATPase IIA
0.519 0.0221 IPI00024368.1 ATP9A (ATPIIA, KIAA0611) 119 Membrane
21 DNA replication licensing factor
MCM2
0.528 0.0292 IPI00184330.5 MCM2 (BM28, CDCL1,
KIAA0030)
102 Nucleus
22 Splice isoform long of splicing
factor, proline- and
glutamine-richc,d
0.475 0.0179 IPI00010740.1 SFPQ (PSF) 76 Nucleus
23 Collagen-binding protein 2
precursorc,d
0.534 0.0114 IPI00032140.2 SERPINH1 (SERPINH2,
CBP2, HSP47, Colligin)
46 ER
24 Small nuclear ribonucleoprotein
SM D2c,d
0.495 0.0412 IPI00017963.1 SNRPD2 (Sm-D2) 13.5 Nucleus
25 4F2 cell surface antigen heavy
chainc,d
0.546 0.05 IPI00027493.1 SLC3A2 (MDU1) 58 Membrane
26 Growth factor receptor-bound
protein 7
0.483 0.038 IPI00448767.3 GRB7 60 u
27 Copine I 0.507 0.0221 IPI00018452.1 CPNE1 (CPN1) 59 u
28 Serum amyloid A protein precursor 0.442 0.0055 IPI00022368.1 SAA1 (SAA2) 13.5 u
29 Ephrin type-A receptor 2 precursor 0.503 0.0221 IPI00021267.1 EPHA1 (ECK) 108 Membrane
30 T-complex protein 1,  subunitc,d 0.492 0.05 IPI00018465.1 CCT7 (TCP-1, CCTH) 59 Cytoplasm
31 Guanine nucleotide-binding protein
 subunit 4c,d
0.53 0.0403 IPI00012451.1 GNB4 37 u
32 Metalloprotease 1 0.494 0.022 IPI00219613.3 PITRM1 (hMP1) 117 Mitochondrion
33 C-1-Tetrahydrofolate synthase,
cytoplasmicc
0.485 0.0275 IPI00218342.9 MTHFD1 (MTHFC) 101 Cytoplasm
34 Predicted: septin 8 0.54 0.0179 IPI00022082.4 SEPT8 (KIAA0202) 50 u
35 Acetolactate synthase homolog 0.465 0.0135 IPI00549240.1 OR10B1P (ILVBL) 68 u
36 Predicted: hypothetical protein
XP_114317
0.511 0.0085 IPI00145623.1 RPL22L1 15–21 u
37 Prefoldin subunit 6 0.512 0.0395 IPI00005657.1 PFDN6 (HKE2) 14.5 Cytosol
38 NADH-cytochrome b5 reductase
c,d 0.395 0.0071 IPI00328415.8 CYB5R3 (DIA1) 34 ER/mitochondrion/
cytoplasm
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TABLE II—continued
No.a Protein description
Ratio of
geometric
means,
OR:PD
Wilcoxon
rank sum IPI Gene symbol
Molecular
mass Localization
b
39 Adenylate kinase isoenzyme 4,
mitochondrial
0.428 0.0036 IPI00016568.1 AK3L1 (AK3, AK4) 25 Mitochondrion
40 Phosphoprotein enriched in
astrocytes 15c
0.481 0.0363 IPI00014850.3 PEA15 (PED) 15 Cytoplasm
41 Thioredoxin domain-containing
protein 5
0.51 0.0496 IPI00171438.2 TXNDC5 (TLP46, ERp46) 48 ER
42 Coronin-1Bc,d 0.425 0.0055 IPI00007058.1 CORO1B 54 Leading edge
43 Ephrin type-B receptor 3 precursor 0.455 0.0077 IPI00289329.1 EPHB3 (ETK2, HEK2) 110 Membrane
44 RAB11 family-interacting
protein 1Bc
0.518 0.0191 IPI00419433.1 RAB11 FIP1 (RCP) 137 Membrane
45 Splice isoform 1 of exocyst
complex component SEC6
0.467 0.0231 IPI00157734.2 EXOC3 (SEC6, SEC6L1) 87 u
46 Splice isoform 1 of protein
C20ORF116 precursor
0.54 0.0266 IPI00028387.3 C20ORF116 36 Secreted protein
47 Hypothetical protein
DKFZP434E248
0.525 0.0221 IPI00300094.5 LSG1 75 u
48 Adenylate kinase 2 isoform Ac,d 2.036 0.0338 IPI00215901.1 AK2 (ADK2) 26 Mitochondrion
49 Trifunctional enzyme  subunit,
mitochondrial precursorc,d
2.105 0.0071 IPI00031522.2 HADHA (HADH) 83 Mitochondrion
50 Nucleosome assembly protein
1-like 1c,d
1.847 0.0275 IPI00023860.1 NAP1L1 (NRP) 45 Nucleus
51 Secretory carrier-associated
membrane protein 1
2.301 0.0055 IPI00005129.6 SCAMP1 40 Membrane
52 Sphingosine-1-phosphate lyase 1d 1.924 0.0135 IPI00099463.2 SGPL1 64 ER membrane
53 Splice isoform 1 of glucosamine-
fructose-6-phosphate
aminotransferase
(isomerizing) 1c,d
2.377 0.0101 IPI00217952.6 GFPT1 (GFAT) 79 u
54 Ubiquinol-cytochrome c reductase
iron-sulfur subunit, mitochondrial
precursorc,d
1.991 0.0236 IPI00026964.1 UQCRFS1 30 Mitochondrion
55 U6 snRNA-associated SM-like
protein LSM2
1.906 0.0394 IPI00032460.3 LSM2 (G7B) 10 Nucleus
56 Lisch protein, isoform 2 2.178 0.0084 IPI00409640.1 LSR (LISCH) 71 Membrane
57 Splice isoform 1 of epsin 4 2.385 0.0064 IPI00291930.5 CLINT1 (EPN4) 68 Cytoplasm
58 Endothelial protein C receptor
precursor
1.932 0.0178 IPI00009276.1 PROCR (EPCR) 30 Membrane
59 Annexin VI isoform 2c,d 2.035 0.0114 IPI00002459.3 ANXA6 75 u
60 Pyridoxine-5-phosphate oxidase 2.081 0.0238 IPI00018272.3 PNPO 30 u
61 Ectonucleotide pyrophosphatase/
phosphodiesterase 1d
2.087 0.0193 IPI00184311.2 ENPP1 (NPPS, PC1) 105 Membrane
62 Protein C20ORF178, charged
multivesicular body protein 4bc,d
1.997 0.0275 IPI00025974.3 CHMP4B (SHAX1) 25 Cytoplasm
63 Occludind 1.848 0.0178 IPI00003373.1 OCLN 59 Membrane
64 Adipose most abundant gene
transcript 2c
2.099 0.0141 IPI00020017.1 APM2 (C10ORF116) 8 u
65 Eukaryotic translation initiation
factor 3 subunit 4
2.413 0.0062 IPI00290460.3 EIF3F 36 u
66 Hypothetical protein MGC5395c,d 1.896 0.05 IPI00031605.1 AHNAK 16 u
67 Splice isoform 2 of
methylcrotonoyl-CoA
Carboxylase  chain,
mitochondrial precursor
1.902 0.0066 IPI00294140.4 MCCC2 (MCCB) 58 Mitochondrion
68 Tubulin -3 chainc,d 1.907 0.009 IPI00013683.2 TUBB3 (TUBB4) 50 u
69 KIAA2014 protein (formin-like
protein 1)
2.091 0.0236 IPI00385874.4 KIAA2014 117 u
70 Hypothetical protein FLJ90697 2.348 0.0377 IPI00329600.3 u
71 Hypothetical protein, isoform 1 of
protein CDV3 homolog
1.986 0.0193 IPI00014197.1 CDV3 22–27 u
72 ATP synthase oligomycin
sensitivity conferral protein,
mitochondrial precursorc,d
2.153 0.0179 IPI00007611.1 ATP5O (ATPO) 23 Mitochondrion
73 Ubiquilin-2 1.843 0.0412 IPI00409659.1 UBQLN2 (PLIC2) 66 Cytoplasm/nucleus
74 Ubiquitin and ribosomal protein
S27Ac,d
2.273 0.0071 IPI00179330.5 RP27A 18 Ribosome
75 Tubulin -1 chainc,d 1.953 0.0222 IPI00007750.1 TUBA1 50 u
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inating protein in the putative protein profile was splice iso-
form 2 of basigin precursor (number 13 in Table II), also
described in the literature as CD147 or EMMPRIN.
Multiple isoforms of EMMPRIN have been described that
are identical in their C-terminal sequence but vary in length
and sequence at the N-terminal part of the protein (Entrez-
Gene 682). In our final, non-redundant protein list we report
the identification of isoforms 1 and 2 by five and six peptides,
respectively (supplemental Table S1). Only one of the six
peptides (AAGTVFTTVEDLGSK) was unique for isoform 2.
Isoform 1 is the longer variant of 385 amino acids, whereas
isoform 2 lacks amino acids 24–139. Peptide AAGTVFTTV-
EDLGSK is uniquely positioned at the splice site in which the
first two amino acids (AA) are positioned at residues 22 and 23
TABLE II—continued
No.a Protein description
Ratio of
geometric
means,
OR:PD
Wilcoxon
rank sum IPI Gene symbol
Molecular
mass Localization
b
76 ATP synthase  chain,
mitochondrial precursorc,d
1.947 0.0412 IPI00440493.2 ATP5O (ATPO) 60 Mitochondrion
77 Chaperonin containing TCP1,
subunit 3c,d
1.872 0.0412 IPI00290770.2 CCT3 60 Cytoplasm
78 Nascent polypeptide-associated
complex  subunitc,d
2.159 0.0143 IPI00023748.3 NACA (HSD48) 23 Cytoplasm/nucleus
79 Emerin 2.189 0.0178 IPI00032003.1 EMD 29 Nuclear inner
membrane
80 Hypothetical protein KIAA0152c,d 1.974 0.0412 IPI00029046.1 KIAA0152 32 Membrane
81 Histone H1.5c,d 2.533 0.05 IPI00217468.2 HIST1H1B (H1F5) 23 Nucleus
82 Cation channel TRPM4B 2.03 0.0465 IPI00294933.6 TRPM4B (TRPM4) 134 Membrane
83 Calcyclinc,d 2.122 0.0363 IPI00027463.1 S100A6 (CACY) 10 Cytoplasm/nucleus
84 Splice isoform 2 of GDNF family
receptor  1 precursor
2.26 0.0184 IPI00220291.1 GFRA1 (GDNFRA, TRNR1) 51 Cell membrane
85 Complement component 1, Q
subcomponent-binding protein,
mitochondrial precursorc,d
2.222 0.0274 IPI00014230.1 C1QBP (GC1QBP) 31 Mitochondrion
86 Chloride intracellular channel
protein 4c,d
2.023 0.0275 IPI00001960.2 CLIC4 29 Cytoplasm/
mitochondrion
87 Eukaryotic translation initiation
factor 3 subunit 6c,d
2.076 0.0178 IPI00013068.1 EIF3E (INT6) 52 Cytoplasm
88 Protein-disulfide isomerase A4
precursorc,d
2.157 0.0275 IPI00009904.1 PDIA4 (ERP70) 73 ER
89 Hypothetical protein MGC5352c,d 1.867 0.0394 IPI00063242.3 PGAM5 28 u
90 Splice isoform 1 of polypeptide
N-acetylgalactosaminyl-
transferase 3d
2.229 0.0066 IPI00004670.1 GALNT3 73 Golgi
91 OTTHUMP00000028732
(thioredoxin, mitochondrial
precursor)
1.823 0.0462 IPI00017799.3 TXN2 (TRX2) 18–22 Mitochondrion
92 Fatty acid-binding protein,
epidermal
2.203 0.0075 IPI00007797.1 FABP5 15 Cytoplasm
93 Programmed cell death
6-interacting protein,
PDCD6IP proteinc,d
2.202 0.0199 IPI00246058.3 PDCD6IP (AIP1) 97 Cytoplasm
94 Ezrin-radixin-moesin-binding
phosphoprotein 50c,d
2.42 0.0025 IPI00003527.3 SLC9A3R1 (EBP50,
NHERF1)
39 Intracytoplasmic
membrane,
actin
cytoskeleton
95 Splice isoform 1 of ubiquitin
thiolesterase protein
1.974 0.05 IPI00549574.2 OTUB1 u
96 Endozepinec,d 2.184 0.0211 IPI00010182.3 ACBP (DBI, EZ) 10 u
97 Phosphoribosylformylglycinamidine
synthase
2.221 0.0177 IPI00004534.3 PFAS (KIAA0361) 145 Cytoplasm
98 Histidine triad nucleotide-binding
protein 1c
1.853 0.0274 IPI00239077.4 HINT1 (PKCI1) 14 Cytoplasm/nucleus
99 BAG family molecular chaperone
regulator-3
1.97 0.0175 IPI00000644.3 u
100 Exocyst complex component
SEC8d
1.856 0.0109 IPI00059279.5 EXOC4 (KIAA1699, SEC8) 110 u
a Numbering according to Fig. 4.
b u, data unknown in database; ER, endoplasmic reticulum.
c Presence verified in individual tumors by MS/MS.
d Presence verified in individual tumor MS survey spectrum and quantified by AMT database match.
e Validated by immunohistochemistry.
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and the third amino acid (Gly) is positioned at residue 140 in
the full-length sequence. Therefore, this peptide sequence is
specific for isoform 2. The raw mass spectrum for EMMPRIN
peptide AAGTVFTTVEDLGSK (Mr 	 1,496.75 and m/z 	
748.38) showed a 3-fold higher intensity for the PD sample
(Fig. 3B) in comparison with the OR sample (Fig. 3A). The
spectra also showed that there is no significant difference in
peak intensity between OR and PD for the second feature
appearing at m/z 749.76, suggesting that the observed differ-
ence in peak intensity for the AAGTVFTTVEDLGSK peptide is
not an artifact introduced by e.g. loading differences. It needs
to be mentioned, however, that we did not use single spectra
to determine abundance ratios of peptides but LC-MS feature
intensity, which is defined as a sum of intensities of all mem-
bers of the unique mass class. Using LC-MS feature intensity,
we investigated the relative abundance of three EMMPRIN
peptides across all of the samples. The peptides AAGTVFT-
TVEDLGSK and GGVVLKEDALPGQK were present in virtually
all samples and clearly showed a 2–3-fold increase in abun-
dance in PD samples. SESVPPVTDWAWYK peptide was only
present in a few samples but showed the same increase in PD
(Fig. 3C). This increase in relative peptide abundance there-
fore correlated very well with the observed 2-fold increase of
EMMPRIN at the protein level (Fig. 3D).
To test the predictive power of the putative profile of 100
proteins within the two sample sets, supervised hierarchical
clustering was performed, represented as a tree-shaped
dendrogram (Fig. 4). Vertically the different proteins are
listed numbered from 1 to 100 from top to bottom. Horizon-
tally the different samples are listed. Based on their average
relative abundances, OR and PD samples were effectively
separated from each other as illustrated by the two main
clusters in the dendrogram (Fig. 4). Separation of the sam-
ples was based on higher (red) and lower (blue) than median
abundance of each protein within all samples. Furthermore
the length of the dendrogram arms shows that some sam-
FIG. 3. EMMPRIN differential pep-
tide and protein abundance. Repre-
sentative mass spectra of an LC-MS fea-
ture identified as EMMPRIN peptide
AAGTVFTTVEDLGSK in OR (A) and PD
(B) indicate a 3-fold increase in intensity
for PD sample. C, relative abundance
ratios of four EMMPRIN peptides in OR
(gray) and PD (black) samples. D, aver-
age relative abundance of EMMPRIN
protein in all OR and PD samples. p
value was calculated using the Wilcoxon
rank sum test. Box-Whisker plot in which
each dot represents the value of a sam-
ple, and the error bars show the highest
and lowest value. The line in the box
represents the mean value.
FIG. 4. Hierarchical clustering of OR and PD samples. Red and
blue colors indicate relative high and low protein abundance, respec-
tively, and white equals median abundance. Gray bars represent
sample and protein clusters. The length of the tree arms is inversely
correlated with similarity. Proteins are listed vertically from top to
bottom and numbered from 1 to 100 in the same order as in Table II.
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ples (replicates) show more similarity to each other than to
the rest of the samples as expected. The order of the
proteins numbered from 1 to 100 is identical to the order
and numbering in Table II.
Similar results were obtained by PCA (supplemental Fig. 2).
In the PCA complex information is reduced to three principal
components, represented by the x, y, and z axes. Samples are
visualized in a three-dimensional plot and cluster according to
their relative protein abundance. From this PCA it is clear that,
in this sample set, OR (green squares) and PD samples (red
squares) were completely separated from each other based
on their protein abundance profile.
To verify that individual peptides showed differential abun-
dance similar to that of their corresponding proteins, we per-
formed hierarchical clustering on all peptides corresponding
to the putative 100-protein profile. As expected, clustering
based on peptides resembled the results of protein clustering
(data not shown).
Verification of Differential Protein Abundance—Our next
goal was to verify the presence and abundance level of all
profile proteins in separate tumor samples. Because we used
pooled microdissected tumor cells for the discovery study,
information on the single tumor level as well as the relation
with clinical factors was lost. To verify our putative profile
proteins, we performed targeted LC-MS/MS analyses using
an inclusion list (supplemental Table S4) compiled from the
m/z values of the peptides that corresponded to the 100
putative profile proteins. We prepared whole tissue protein
lysates from tumors (eight OR and 12 PD) with a high tumor
cell content (70%) so that microdissection could be omitted.
Using this approach, we identified and therefore verified the
presence of 50 proteins from the inclusion list. In addition,
peak intensities of survey mass spectra (on average 14,000
LC-MS features per sample) were used for quantitation. In this
case, peptide identity was derived by matching LC-MS fea-
tures from survey spectra to the composite breast cancer cell
line AMT tag database. This resulted in the identification and
quantitation of 47 target proteins of which 42 were also iden-
tified by MS/MS sequencing (Fig. 5). Overall a total of 55
proteins (50 by MS/MS sequencing and five additional by
LC-MS feature (survey mass spectra) matching with the AMT
database of the 100-putative protein list) were verified in an
independent targeted LC-MS/MS experiment. The 47 pro-
teins for which relative abundance was available were used in
further analyses. Surprisingly the top discriminating protein in
the original profile, EMMPRIN, was not identified through this
targeted approach. Raw MS/MS data obtained for verified
proteins and relative abundance ratios for verified proteins are
listed in supplemental Tables S5 and S6, respectively.
Relative abundances of the 47 verified proteins were sta-
tistically analyzed using either Wilcoxon rank sum or Stu-
dent’s t test depending on the outcome of a test for normality
based on skewness and kurtosis. Three proteins, ectonucle-
otide phosphatase/phosphodiesterase 1 (ENPP1; number 61
in Table II), guanine nucleotide-binding protein  subunit 4
(GNB4; number 31 in Table II), and ubiquinol-cytochrome c
reductase iron-sulfur subunit mitochondrial precursor
(UQCRFS1; number 54 in Table II) were significantly differen-
tially abundant between OR and PD with p values of 0.043
(Fig. 6A), 0.026 (Fig. 6B), and 0.036 (not shown), respectively
(Table III). ENPP1 was not detected in any of the OR samples
but in five of 12 PD samples (Fig. 6A), whereas GNB4 (Fig. 6B)
and UQCRFS1 were higher in OR samples (Table III). In ad-
dition, eukaryotic translation initiation factor 3 subunit 6/E
(EIF3E) (Fig. 6C), occludin (OCLN), splice isoform 1 of surfeit
locus protein 4 (SURF4), thioredoxin domain-containing pro-
tein 5 precursor (TXNDC5), and ubiquitin and ribosomal pro-
tein S27A (RP27A) showed a trend toward differential abun-
dance (0.05  p  0.1). Mean abundance and 95%
confidence intervals (CIs) are listed in Table III. It needs to be
mentioned that analysis groups for verification were rather
small (eight OR versus 12 PD); thus the outcomes may change
when more samples are analyzed in future studies. Subse-
quently relative abundance of all 47 verified proteins was
coupled to clinical end points of patients. Of these 47 pro-
teins, ENPP1, EIF3E, and GNB4 showed significant associa-
tion with progression-free survival, whereas UQCRFS1 did
not, although it did associate with response as described
above. Kaplan-Meier analysis as a function of ENPP1 status
showed that the presence of ENPP1 was significantly corre-
lated with shorter progression-free survival after the start of
tamoxifen treatment with a hazard ratio (HR) of 1.63 (95% CI,
1.15–2.32; p 	 0.005) (Fig. 6D). Survival analyses as a func-
tion of EIF3E and GNB4 levels were performed after dividing
the relative abundance levels into low  median versus high
because low and median level survival curves were superim-
posable. High levels of EIF3E and GNB4 were significantly
associated with prolonged progression-free survival with HRs
of 0.22 (95% CI, 0.07–0.71; p 	 0.01) (Fig. 6E) and 0.24 (95%
CI, 0.07–0.79; p 	 0.02) (Fig. 6F), respectively. In conclusion,
we were able to associate high GNB4 and EIF3E levels with a
favorable outcome and ENPP1 with an adverse outcome on
tamoxifen therapy.
Validation of EMMPRIN and Association with Clinical End
Points—A pivotal step in the process of biomarker discovery
425 8
LC-MS AMT 
DB match: 47
Targeted LC-
MS/MS: 50
Total proteins: 55
FIG. 5. Verification of putative profile proteins. Putative profile
proteins were verified in non-microdissected tumor samples through
targeted MS/MS. Peptide abundance information was retrieved from
peak intensities of MS survey spectra. For protein identification MS
survey spectra were matched with the AMT database (DB).
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is the validation of putative markers in independent patient
cohorts and preferably by using a different methodology,
such as using immunohistochemistry (IHC). In our case,
validation was only performed for the top discriminating
protein, EMMPRIN, because there are no appropriate anti-
bodies available for ENPP1, EIF3E, and GNB4 or for any of
the other differentially abundant proteins we discovered.
The antibody we used in this study was directed against the
C-terminal part of EMMPRIN and therefore recognizes all
splice isoforms.
To independently validate differential EMMPRIN protein
abundance between OR and PD patients, IHC was performed
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FIG. 6. Clinical association of veri-
fied proteins. Differences in relative
abundance ratios between OR (red) and
PD (green) tumors for ENPP1 (A), GNB4
(B), and EIF3E (C) are shown. Shown is
the Kaplan-Meier survival analysis of
time to progression upon tamoxifen
treatment for recurrent breast cancer
patients according to LC-MS abundance
levels. For ENPP1, absence (abs) (green
line) and presence (pres) (red line) of
abundance was compared (D). For
GNB4 (E) and EIF3E (F) low abundance
and medium abundance were grouped
(green line) and compared with high
abundance (red line). The number of pa-
tients at risk in each group is displayed
together with the hazard ration, 95%
confidence interval, and p value. Avg,
average; Cum, cumulative; CI, confi-
dence interval.
TABLE III
Verified differentially abundant proteins
Shown are a subset of putative profile proteins verified in targeted MS/MS experiment with a p value 0.1.
Protein description
Gene
symbol
Higher in  mean/median (95% CI) p value
Guanine nucleotide-binding protein  subunit 4 GNB4 OR 35.1 (65.2 to 4.8) 0.026
Ubiquinol-cytochrome c reductase iron-sulfur
subunit, mitochondrial precursor
UQCRFS1 OR 31.6 (61.0 to 2.3) 0.036
Ectonucleotide pyrophosphatase/
phosphodiesterase 1a
EPP1 PD 0 (0–1.3) 0.043
Thioredoxin domain-containing protein 5 precursora TXNDC5 PD 2.8 (0.02 to 20.3) 0.081
Eukaryotic translation initiation factor 3 subunit 6 EIF3E OR 2.2 (4.8 to 0.3) 0.085
Occludina OCLN OR 0 (1.6 to 0) 0.087
Splice isoform 1 of O15260 Surfeit locus protein 4 SURF4 PD 3.7 (0.8 to 8.3) 0.098
Ribosomal protein S27A RP27A OR 168.1 (376.3 to 40.2) 0.100
a Wilcoxon rank sum.
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using our primary breast cancer TMA. Among the different
tissues, there were 156 breast tumors of patients who re-
ceived first line tamoxifen therapy after recurrence. This set of
tumors had no overlap with the discovery set tumors. In total,
130 tumors showed reproducible IHC staining on the TMA
when assays were performed in triplicate. Patient and tumor
characteristics are described in Table IV. Different staining
outcomes were categorized as undetectable, weak, medium,
and strong membrane staining. Weak membrane staining,
present in 10% of tumor cells, was scored as 1. Medium
membrane staining, present in 10–50% of tumor cells, was
scored as 2. Strong membrane staining, observed in 50%
of tumor cells, was assigned score 3 (Fig. 7). These scoring
outcomes were subsequently related to clinical endpoints. We
observed that none of the CR tumors displayed EMMPRIN
staining, whereas highest EMMPRIN staining (3) was ob-
served in PD tumors (Table V). This finding, originally indicated
using LC-MS-based technology, was thus confirmed by IHC.
For comparison, we defined a “clinical benefit” group com-
posed of tumors showing NC for 6 months, CR, and PR and
a “no clinical benefit” group representing NC for 6 months
and PD tumors. Absence of detectable EMMPRIN levels
showed a significant clinical benefit with an odds ratio of 2.98
(95% CI, 1.32–6.73; p 	 0.009). The presence of detectable
B
No stain
D
2+ stain
1+ stain
C
3+ stain
E
A
FIG. 7. Immunohistochemical staining of EMMPRIN. EMMPRIN
immunohistochemical staining was performed on an independent
sample set of 156 tissues using TMA. A, overview of TMA; B, nega-
tively stained tissue; C, 1 membrane stain; D, 2 stain; E, 3 stain.
Overview picture was taken at 5 magnification; other pictures were
taken at 100 magnification.
TABLE IV
Patient characteristics
Patient and tumor characteristics for samples included in the vali-
dation set are shown.
ER, estrogen receptor ; PgR, progesterone receptor.
Characteristics Numbers Median Percent
Patients 130 100
Age (years)
Primary surgery 53.5
Start first line 56.5
Menopausal status at start
first line
Pre 40 30.8
Post 90 69.2
ER (fmol/mg protein) 97
PgR (fmol/mg protein) 54.5
Response
Clinical benefit: CR, PR,
S.D.  6 months
77 59.2
No clinical benefit:
S.D.  6 months, PD
53 40.8
Dominant site of relapse
Local regional relapse 15 11.5
Bone 65 50.0
Other 50 38.5
Disease-free interval (months)
12 16 12.3
12–36 59 45.4
36 55 42.3
Nodal status
N0 62 47.7
N1–3 30 23.1
N  3 34 26.2
Unknown 4 3.1
Tumor size
2 cm 67 51.5
2 cm 63 48.5
Tumor grade
Poor 46 35.4
Unknown 52 40.0
Good/moderate 32 24.6 TABLE V
IHC score of EMMPRIN
The average (Avg) EMMPRIN score in tumors grouped by therapy
response is shown.
Avg
score
CR PR
NC  6
months
NC  6
months
PD Total
0 4 20 40 8 25 97
1 0 4 6 3 12 25
2 0 0 2 0 4 6
3 0 0 1 0 1 2
Total 4 24 49 11 42 130
Tamoxifen Resistance Protein Profile in Breast Cancer
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EMMPRIN levels was more frequently observed in premeno-
pausal women (X2 	 11.7; p  0.001) and in patients with a
shorter disease-free interval (X2 	 11.2; p 	 0.004) defined as
the time from primary diagnosis to recurrence (Table VI). In
addition, Cox regression analysis showed that presence of
EMMPRIN significantly correlated with shorter progression-
free survival from the start of tamoxifen treatment (HR, 1.87;
95% CI, 1.25–2.80; p 	 0.002) (Fig. 8). Thus, high EMMPRIN
levels correlate with poor outcome on first line tamoxifen
treatment.
DISCUSSION
We performed a comparative proteomics study using
nano-LC-FTICTR MS analyses of tamoxifen therapy-resis-
tant and therapy-responsive tumor cells isolated from
breast cancer tissue by LCM. This approach proved to be
extremely powerful as exemplified by identification of sev-
eral thousand unique proteins from sub-g quantities of
clinically relevant samples. These efforts resulted in the
identification of a putative protein profile that is associated
with the type of response to tamoxifen therapy. Furthermore
we validated our top discriminating protein, EMMPRIN, in
an independent patient cohort and confirmed its association
with tamoxifen therapy resistance in recurrent breast
cancer.
Protein Identification by Nano-LC-FTICR MS—Many dif-
ferent proteomics technologies are available nowadays that
all aid in the quest for cancer biomarkers. The method of
choice will depend on the type of question asked, the type
of material being investigated, and the availability of re-
sources. Several studies have shown that the combination
of dedicated nano-LC separation coupled to high end FT
MS offers the best potential for in-depth analysis of limited
sample quantity, which is usually the case with clinical
material (23, 28, 36, 37, 40). In the present study, we used
nano-LC-FTICR MS and a composite breast cancer cell line
AMT tag database for the identification of peptides from as
little as 550 ng of protein lysate. Overall we identified over
17,000 unique peptides corresponding to over 2,500 unique
proteins, a significantly larger fraction of the proteome than
attainable with more conventional proteomics techniques
(20, 22). Furthermore we believe there is more to gain if a
breast cancer tissue-specific AMT tag database becomes
available. Although breast cancer cell lines represent as-
pects of normal and malignant breast tissue, it is well known
that cultured cell lines have quite a distinct proteomic profile
compared with primary cells or tissues. This was clearly
demonstrated by Ornstein et al. (18) who compared pro-
teomes of microdissected prostate tumor cells with pro-
teomes of matching cell lines from the same patient. They
showed that protein expression was strikingly altered in
cultured cells, which had less than 20% proteins in common
with uncultured cells (18). Therefore, it is very well possible
that proteins involved in therapy resistance of breast tumors
are not expressed in cell lines and thus are missing from the
AMT tag database used in this study. To overcome this
problem, we are currently constructing an AMT tag data-
base from breast cancer tissues using a selection of tumors
that have distinct phenotypic characteristics. A breast can-
cer tissue-specific AMT tag database will most likely in-
crease the number of identified peptides (i.e. proteome
coverage) in LC-MS analyses, thus increasing our chances
of identifying relevant biomarkers. Proteome coverage
could even be further improved using “smart MS/MS,” e.g.
by fragmenting currently unidentified LC-MS features.
Discovery and Verification of Putative Tamoxifen Therapy
Response-associated Proteins—The putative protein profile
described in this study consists of 100 proteins involved in
a variety of biological processes. These proteins can be
categorized into different functional classes, such as struc-
tural proteins, signaling proteins and kinases, metabolic
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FIG. 8. Kaplan-Meier survival analysis. EMMPRIN abundance
was measured by IHC using TMA and was correlated to time to
progression after the onset of first line tamoxifen treatment. Ab-
sence (abs) of detectable EMMPRIN (green line) was compared with
presence (pres) (1, 2, and 3) of EMMPRIN staining (red line).
TABLE VI
EMMPRIN correlation with clinical factors
EMMPRIN protein abundance correlated with menopausal status and disease-free interval is shown.
EMMPRIN n (%)
Menopausal status Disease-free interval (months)
Pre (%) Post (%) 12 (%) 12–36 (%) 36 (%)
Absent 97 (74.6) 22 (55.0) 75 (83.3) 9 (56.3) 39 (66.1) 49 (89.1)
Present 33 (25.4) 18 (45.0) 15 (16.7) 7 (43.7) 20 (34.9) 6 (10.9)
Total 130 (100) 40 (30.7) 90 (69.2) 16 (12.3) 59 (45.3) 55 (42.3)
Pearson 2 11.7 11.2
p value 0.001 0.004
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enzymes, proteins involved in apoptosis, and others (see
Table II). Several of the putative profile proteins (NAP1L1,
pyridoxine-5-phosphate oxidase, and UQCRFS1) have
been previously associated with tamoxifen therapy resist-
ance in breast cancer (41, 42) or chemotherapy resistance
(SGPL1 and TUBB3) in vitro and in clinical specimens (43–
45) and with aggressiveness of breast cancer (S100A6,
S100A9, CLIC4, EBP50, and OCLN) (46–51).
Because the discovery of putative tamoxifen response-
predictive proteins was performed in pooled samples, it was
important to verify the presence and relative abundance of
these proteins in each individual tumor tissue. Using a tar-
geted MS/MS approach, we successfully identified 55 profile
proteins in individual, non-microdissected tumor lysates and
retrieved quantitative information for 47 of these proteins.
Clearly 45 putative proteins were left unverified in individual
tumor samples, including our top discriminating protein,
EMMPRIN. The relatively low verification rate can be justified
by the use of different samples and LC-MS platforms for the
discovery and verification part of the study. Microdissected
tumor cell lysates were analyzed by ultranarrow LC coupled to
FTICR for discovery, whereas whole tissue lysates represent-
ing a mixture of cell types were analyzed by a standardized
LC-MS/MS platform for verification. Nano-LC-FTICR analysis
yielded an average of 40,000 LC-MS features, whereas
LC-MS/MS Orbitrap analysis detected on average 14,000
LC-MS features. Therefore, the nano-LC-FTICR platform
yielded 3 higher proteome coverage and, one can spec-
ulate, resulted in a similar improvement in sensitivity (i.e. limit
of detection). Similarly we only used information on accurate
mass in targeted MS/MS experiments because it was not
possible to use NET information as an inclusion criterion with
the software version available at the time. The addition of NET
information as an inclusion criterion will most likely increase
the success rate of target peptide identification through
MS/MS in future studies using updated instrument control
software. The compilation of these effects (i.e. LC-MS plat-
form with lower overall sensitivity and inadequate targeted
MS/MS strategy) resulted in a failure to confirm the identity of
our top discriminating protein as EMMPRIN in the verification
study.
Nevertheless the presence of 55 putative profile proteins
was verified, and based on the abundance ratios, ENPP1,
UQCRFS1, and GNB4 were confirmed to be significantly dif-
ferentially abundant between OR and PD tumors. In addition
ENPP1, EIF3E, and GNB4, were significantly associated with
time to progression upon first line tamoxifen treatment of
recurrent breast cancer. So far, no link between ENPP1 or
GNB4 and breast cancer or response to tamoxifen has been
described, although ENPP1 overexpression and polymor-
phisms have been repeatedly associated with insulin resist-
ance and obesity (52, 53). Obesity is a risk factor for breast
cancer (54), and insulin resistance may be linked to tamoxifen
therapy resistance.
EIF3E protein expression has been shown to be signifi-
cantly decreased in breast cancer, which was frequently as-
sociated with loss of heterozygosity at the Int-6/eIF3-p48
locus (55). EIF3E is ubiquitously expressed and highly con-
served, and it encodes the p48 subunit of the translation
initiation factor eIF3, also named INT6. In a multiplex tissue
immunoblotting study by Traicoff et al. (56), EIF3E expression
was determined in 124 breast cancer tissues. It was shown
that breast tissues clustered according to high or low EIF3E
expression, and this segregation was not dependent on tumor
stage. Furthermore EIF3E expression positively correlated
with tumor suppressors, such as p53, suggesting a function in
the same signaling pathway (56). It was postulated that EIF3E
has diverse functions in cell growth in addition to translation
initiation, including tumor suppressive properties. This was
particularly clearly shown in studies where truncation or
knockdown of EIF3E induced angiogenesis and tumor forma-
tion (57, 58). This tumor-suppressive role correlates well with
the elevated abundance of EIF3E in OR tumors and its con-
tribution to prolonged progression-free survival upon tamox-
ifen treatment.
Validation of EMMPRIN—The validation study was focused
on our top discriminating protein, EMMPRIN, which is known
to be involved in breast cancer and for which an appropriate
antibody is conveniently available. EMMPRIN has been pre-
viously described to play a role in tumor cell invasion and
metastasis (59). In particular, it acts through up-regulation of
the urokinase-type plasminogen activator system, thereby
promoting tumor cell invasion (60). In an immunohistochemi-
cal study using high density breast cancer tissue microarrays,
it was shown that positive EMMPRIN staining correlated with
various histopathological parameters, in particular with de-
creased tumor-specific survival in postmenopausal patients
(61). EMMPRIN is up-regulated in many types of cancer (62),
supporting the previous findings that the involvement of
EMMPRIN in urokinase-type plasminogen activator deregula-
tion may be a universal phenomenon in tumorigenesis and is
not restricted to breast cancer. In addition, EMMPRIN has
been recently shown to predict response and survival follow-
ing cisplatin-containing chemotherapy in patients with ad-
vanced bladder cancer (63). An IHC analysis in 101 advanced
bladder cancer patients showed that high EMMPRIN expres-
sion strongly correlated with shorter survival time, in particular
in patients with metastatic tumors, and that response to
chemotherapy could also be predicted with an odds ratio of
4.41 (63). In our study, high expression of EMMRPIN was
more frequently observed in PD than OR tumors, and it was
significantly associated with an early tumor progression after
the onset of first line tamoxifen treatment in recurrent breast
cancer. Combining our results with previous findings, one can
speculate that EMMPRIN-induced tumor aggressiveness may
be the result of therapy resistance in general (i.e. tamoxifen
and chemotherapy) and that this mechanism is not restricted
to breast cancer.
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Concluding Remarks—In this study we demonstrated
quantitative analysis of minute amounts of clinically relevant
tumor tissues using ultrasensitive nano-LC-FTICR technol-
ogy. These analyses have put forward a putative protein pro-
file that may predict the outcome of response for tamoxifen
therapy in breast cancer patients. Whether this profile as a
whole is a good predictor for tamoxifen therapy response in a
larger, independent group of patients and whether it is appli-
cable to chemotherapy as well will be the subject of further
investigations.
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